Is CPRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,084 people get CPRX articles and Market Currents by email alert.

Get email alerts on CPRX »

HEADLINES:

Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 2 Comments
Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results

GlobeNewswire (May 16, 2013)
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Tom Welch • Wed, May 1 • 2 Comments
Catalyst Deserves The Attention
Veziris Ventures • Tue, Apr 23 • 4 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2012 Financial Results

GlobeNewswire (Apr 2, 2013)
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)

GlobeNewswire (Mar 27, 2013)
Catalyst Pharmaceutical And Dynavax Are Buys Now
BuySellShort • Fri, Mar 8 • 1 Comment
Catalyst Pharmaceutical Partners to Present at 25th Annual ROTH Conference

GlobeNewswire (Mar 7, 2013)
Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations

GlobeNewswire (Mar 5, 2013)
Catalyst Pharmaceutical Partners Launches New Website

GlobeNewswire (Feb 21, 2013)
Catalyst Pharmaceutical Partners Provides Update on Research and Development Pipeline

GlobeNewswire (Feb 11, 2013)
Catalyst Pharmaceutical Partners to Present at 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 5, 2013)
Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

GlobeNewswire (Dec 27, 2012)
Catalyst Pharmaceutical Partners Announces Automatic Conversion of $5 Million Promissory Note Into Shares of Common Stock

GlobeNewswire (Dec 11, 2012)
Smart Day Traders Ring The Register On Acadia And Zalicus
James Stocklasar Thomas Jr. • Wed, Nov 28, 2012 • 15 Comments
Why Cash Overrules The Momentary Market Bounce
James Stocklasar Thomas Jr. • Tue, Nov 27, 2012 • 14 Comments
Catalyst Pharmaceutical Partners Announces Third Quarter 2012 Financial Results

GlobeNewswire (Nov 15, 2012)
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction

GlobeNewswire (Nov 8, 2012)
Catalyst Pharmaceutical Partners and BioMarin Pharmaceutical Enter Into Strategic Collaboration for Firdapse(TM) in North America

GlobeNewswire (Oct 31, 2012)

To learn more about Seeking Alpha Pro, click here.

Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 2 Comments
Catalyst Deserves The Attention
Veziris Ventures • Tue, Apr 23 • 4 Comments
Catalyst Hoping For Good Phase II Results
Brian L. Wilson • Fri, Oct 12, 2012 • 10 Comments
Analysis Of Catalyst Pharmaceutical's Vigabatrin And Its Potential For Phase IIb Trial Success
Ankit Desai • Thu, Oct 4, 2012 • 23 Comments
More Evidence For Catalyst's Potential Vigabatrin Success
James Stocklasar Thomas Jr. • Mon, Sep 17, 2012 • 23 Comments
Buying Into Catalyst Pharma's Fast Tracked Vigabatrim On Friday
James Stocklasar Thomas Jr. • Fri, Sep 14, 2012 • 36 Comments
Strong Catalyst Run-Up Trade: Catalyst Pharma's Upcoming Phase II Data
Scott Matusow • Fri, Aug 24, 2012 • 22 Comments
Traders Circling Catalyst Pharmaceutical Partners
Richard Cavalli • Wed, Jul 25, 2012 • 11 Comments
4 Reasons To Buy Catalyst Pharmaceuticals
Jorge Aura • Tue, Jul 24, 2012 • 10 Comments
Update On The Trials Of Catalyst Pharma's CPP-109 In Cocaine Addiction And CPP-115 Pre-Clinical Studies
Smith On Stocks • Wed, Jan 25, 2012 • 1 Comment
Catalyst Pharma: Awaiting Key Clinical Trial Results For CPP-109 For Treating Cocaine Addiction
Smith On Stocks • Tue, Jan 24, 2012 • 4 Comments
Catalyst Pharmaceutical May Need More Stimulus
ScriptVolume • Mon, Dec 12, 2011

Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform
Tom Welch • Wed, May 1 • 2 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
Catalyst Pharmaceutical And Dynavax Are Buys Now
BuySellShort • Fri, Mar 8 • 1 Comment
Smart Day Traders Ring The Register On Acadia And Zalicus
James Stocklasar Thomas Jr. • Wed, Nov 28, 2012 • 15 Comments
Why Cash Overrules The Momentary Market Bounce
James Stocklasar Thomas Jr. • Tue, Nov 27, 2012 • 14 Comments
Why Acadia May Be This Year's Holiday Prize
James Stocklasar Thomas Jr. • Wed, Oct 17, 2012 • 28 Comments
Savient Pharmaceuticals May Continue To Run Higher
Scott Matusow • Tue, Oct 9, 2012 • 7 Comments
3 Best Biotech Stocks For This Week (Part III)
Jorge Aura • Mon, Sep 24, 2012 • 17 Comments
Under Construction Rehash: Buy Acadia And Astex
James Stocklasar Thomas Jr. • Thu, Sep 20, 2012 • 24 Comments
3 Biotechs With Increased Short Interest And Imminent Catalysts Coming Soon
R.S. Analytics • Tue, Sep 18, 2012 • 14 Comments
3 Companies With Exciting Phase II Trial Data Close Out 2012
Chemistfrog • Mon, Sep 10, 2012 • 17 Comments
3 Speculative Biotech Stocks To Electrify Your Boring Portfolio
Michael J. Ray • Mon, Sep 3, 2012 • 15 Comments
3 Healthcare Companies With Insider Buys: July 3rd - July 5th
Markus Aarnio • Sat, Jul 7, 2012 • 17 Comments
3 Healthcare Companies With Insider Buys: June 29th - July 3rd
Markus Aarnio • Wed, Jul 4, 2012 • 9 Comments
Merck Suffers Same Flaw As Facebook
Richard Cavalli • Tue, May 29, 2012 • 5 Comments
7 Biotechs Under $8 Poised For A January Surge
Rougemont • Thu, Dec 15, 2011 • 3 Comments
7 Stocks Under $6 Poised To Double In 2012
Hawkinvest • Thu, Nov 24, 2011 • 7 Comments
Trade Ideas From Last Week's Big Biotech News Movers
GuruFundPicks • Mon, Nov 21, 2011
Biotech Takeovers Could Heat Up These Stocks
Rougemont • Fri, Nov 18, 2011 • 4 Comments
6 Biotechs That Could See Huge Gains (Like Inhibitex)
Rougemont • Fri, Nov 11, 2011 • 1 Comment

There are no Transcripts on CPRX.

Catalyst Pharmaceutical Partners Reports First Quarter 2013 Financial Results

GlobeNewswire (May 16, 2013)
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2012 Financial Results

GlobeNewswire (Apr 2, 2013)
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse(TM)

GlobeNewswire (Mar 27, 2013)
Catalyst Pharmaceutical Partners to Present at 25th Annual ROTH Conference

GlobeNewswire (Mar 7, 2013)
Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations

GlobeNewswire (Mar 5, 2013)
Catalyst Pharmaceutical Partners Launches New Website

GlobeNewswire (Feb 21, 2013)
Catalyst Pharmaceutical Partners Provides Update on Research and Development Pipeline

GlobeNewswire (Feb 11, 2013)
Catalyst Pharmaceutical Partners to Present at 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 5, 2013)
Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

GlobeNewswire (Dec 27, 2012)
Catalyst Pharmaceutical Partners Announces Automatic Conversion of $5 Million Promissory Note Into Shares of Common Stock

GlobeNewswire (Dec 11, 2012)
Catalyst Pharmaceutical Partners Announces Third Quarter 2012 Financial Results

GlobeNewswire (Nov 15, 2012)
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction

GlobeNewswire (Nov 8, 2012)
Catalyst Pharmaceutical Partners and BioMarin Pharmaceutical Enter Into Strategic Collaboration for Firdapse(TM) in North America

GlobeNewswire (Oct 31, 2012)
Catalyst Pharmaceutical Partners Updates Guidance on Timing of Top-Line Data From CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction

GlobeNewswire (Sep 26, 2012)
Catalyst Pharmaceutical Partners Announces Commencement of CPP-109 Investigator-Sponsored Study in Patients With Treatment Refractory Tourette's Disorder

GlobeNewswire (Sep 24, 2012)
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 14th Annual Healthcare Conference

GlobeNewswire (Sep 6, 2012)
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced $6 Million Registered Direct Offering

GlobeNewswire (Aug 30, 2012)
Catalyst Pharmaceutical Partners, Inc. Raises $6 Million in Registered Direct Offering

GlobeNewswire (Aug 28, 2012)
Catalyst Pharmaceutical Partners Announces Second Quarter 2012 Financial Results

GlobeNewswire (Aug 15, 2012)
Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule

GlobeNewswire (Aug 3, 2012)

CPRX vs. ETF Alternatives

Company Description

Currently, there's no company description for CPRX.

Sector: Healthcare

Industry: Drugs - Generic

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, April 23, 12:56 PM Midday top 10 gainers: SCON +118%. MEMS +49%. CZR +29%. NFLX +24%. ARL +18%. CPLA +18%. VECO +17%. HSTM +17%. SANM +16%. ILMN +15%.
Midday top 10 losers: CPRX -15%. IIVI -13%. UNTK -13%. ABIO -13%. CASM -10%. EFUT -9%. GASS -9%. TAX -8%. SIFY -7%. USTR -7%. Comment! [On the Move]
Thursday, April 18, 10:30 AM Catalyst Pharmaceutical (CPRX +13%) gets a big boost from an initiation on valuation at Aegis Capital with a Buy rating and a price target of $2.50 per share, representing a lofty fourfold increase off current levels. Comment! [Healthcare, On the Move]
Wednesday, March 27, 11:56 AM Catalyst Pharmaceutical Partners (CPRX -1.9%) slips into the red after opening +8% on the back of its earlier announcement that the independent Data Monitoring Committee overseeing CPRX's Phase III clinical trials of Firdapse, a potential treatment for Lambert-Easton Myasthenic Syndrome, gave the go-ahead to continue the trial as planned based on a review of safety and clinical data. Comment! [Healthcare, On the Move]
Wednesday, March 27, 8:14 AM Catalyst Pharmaceutical (CPRX +3.9%) receives a recommendation from the Data Monitoring Committee (DMC) to continue Phase III trials of the firm's Firdapse treatment for Lambert-Easton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder characterized by muscle weakness of the limbs, and is often associated with an underlying malignancy. (PR) Comment! [Healthcare, On the Move]
Monday, February 11, 9:30 AM Catalyst Pharmaceutical (CPRX) discontinues the development of its CPP-109 for the treatment of cocaine and methamphetamine addiction after it failed a Phase IIb trial. Meanwhile, Catalyst expects to complete by the end the of the year the enrollment of 30 patients with the rare autoimmune disease LEMS for a trial of the company's Firdapse drug. Catalyst also believes its CPP-115 treatment for infantile spasms could be more potent and have fewer side effects than vigabatrin. Comment! [Healthcare]
Tuesday, December 11, 2012, 2:02 PM Catalyst Pharmaceutical Partners (CPRX -2.4%) says it's issued 6,666,667 shares of its authorized but unissued common stock to BioMarin Pharmaceutical (BMRN +2.5%) upon the automatic conversion of a $5M loan that CPRX received from BMRN in October in connection with it's licensing of the North American rights to Firdapse. The shares were issued at a conversion price of $0.75 per share. Comment! [Healthcare, On the Move]
Thursday, November 8, 2012, 12:45 PM Midday top 10 gainers: DUSA +38%. PRMW +23%. ARX +22%. RST +22%. ES +19%. FALC +18%. UPIP +18%. SAPE +17%. PRSC +17%. MWW +17%. Midday top 10 Losers: CPRX -62%. BCRX -39%. COBR -24%. PRSS -21%. CALI -21%. UPG -20%. SVNT -19%. TRU -19%. MITK -19%. PANL -18%. Comment!
Thursday, November 8, 2012, 12:22 PM Catalyst Pharmaceutical (CPRX -62%) craters after saying earlier that CPP-109, its potential cocaine addiction treatment, failed to meet its primary endpoint versus a placebo in Phase II studies. The data also showed that two key secondary endpoints, a significantly larger increase in cocaine negative urines and a significant decrease in the weekly fraction of use days in medication-treated subjects, also were not met. Comment! [Healthcare, On the Move]
Thursday, November 8, 2012, 9:10 AM Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move]
Wednesday, October 31, 2012, 3:02 PM Catalyst Pharmaceutical (CPRX -6.6%) slides after announcing a collaboration agreement with BioMarin Pharmaceutical (BMRN -4.5%) for the North American rights to Firdapse, a treatment of Lambert-Eaton Myasthenic Syndrome. According to the agreement, CPRX will license exclusive rights to Firdapse, while BMRN will make a $5M investment in CPRX for program advancement. Firdapse is an orphan product that has already been approved in the E.U. and is undergoing phase III clinical trials in the U.S. Comment! [Healthcare, On the Move]
Wednesday, September 26, 2012, 12:45 PM Midday top 10 gainers: LPHI +112%. CTC +18%. AM +17%. STSI +15%. KCG +11%. WCBO +11%. CAMP +10%. DIAL +10%. SCMP +10%. SVN +8%.
Top 10 Losers: PATH -27%. BTH -19%. OMN -14%. RMKR -13%. CPRX -13%. TISA -12%. GEVO -12%. MITK -12%. OINK -12%. TSTC -11%. Comment! [On the Move]
Wednesday, September 26, 2012, 9:10 AM Premarket gainers: SCMP +13%.
Losers: PATH -32%. BTH -24%. CPRX -20%. GEVO -12%. FTNT -7%. JBL -6%. GTAT -6%. Comment! [On the Move]
Wednesday, September 26, 2012, 9:08 AM Catalyst Pharmaceutical Partners (CPRX) tumbles, -20% premarket, after announcing a delay in top-line results from a study of its vigabatrin phase II(b) trial for cocaine addiction. The Department of Veterans Affairs Cooperative Studies Program won't be able to provide results around end of month as expected, but the company still expects a report "significantly earlier than we had originally anticipated." Comment! [Healthcare, On the Move, Breaking News]
Monday, September 24, 2012, 9:10 AM Premarket gainers: LPH +39%. RMBS +13%. TIVO +10%. STSI +10%. HEB +8%. CPRX +6%.
Losers: PPHM -85%. QCOR -28%. GTAT -8%. FB -6%. AKS -5%. 1 Comment [On the Move]
Wednesday, September 19, 2012, 9:10 AM Premarket gainers: ACHN +12%. DCTH +9%. CPRX +9%. CBRL +7%. DRYS +7%. BVSN +6%. ANTH +6%.
Losers: IDIX -9%. GTAT -7%. 1 Comment [On the Move]
Monday, September 17, 2012, 9:10 AM Premarket gainers: IRIS +45%. GNOM +15%. ODP +10%. KTOS +9%. CPRX +9%. TSLA +8%. DVAX +7%. CTIC +6%.
Losers: THLD -23%. Comment! [On the Move]

oldorv
$LLEN, Long, Wow! see also $BRK.B, $CPRX, $$PSWS, $SKTO, $RTIX. Keep on rockin'.
May 8, 10:29 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

oldorv
$CPRX,$PSWS,$SKTO, interesting micros. Long......
Apr 24, 10:46 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

oldorv
$CPRX, $LLEN, LONG, 2 very fine micros...
Apr 23, 8:34 AM
Reply (3)

• !Report Abuse
View all 3 replies
Spitgray: Bought!!!
Apr 24, 3:51 PM
• !Report Abuse
oldorv: GOOD LUCK TO US
Apr 24, 3:59 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
@CPRX lesson learned = question it next time company does financing deal before data is out, also, take profits on runs!
11/8/12
Reply (14)

• !Report Abuse
View all 14 replies
Iron K: I'm in the same boat I was looking at the filing and the 5M I'm going to hold for at least 30 days to see the affect of it.
11/9/12
• !Report Abuse
Iron K: Also maybe CPP-115 increased dosage will have a positive affect? (lol)
11/9/12
• !Report Abuse
Add a reply...

140 characters

stockperks
Hope you guys all bailed out of CPRX before today's death spiral...
11/8/12
Reply (1)

• !Report Abuse
View all 1 replies
Iron K: Is it worth investing in for their other two orphan drugs coming up?
11/8/12
• !Report Abuse
Add a reply...

140 characters

JoeChang23
what's going on with CPRX guys? Stock is going down instead of rising in anticipation of Phase2b.
11/1/12
Reply (1)

• !Report Abuse
View all 1 replies
uavmx: "BioMarin has invested $5 million in Catalyst, which will convert on a mandatory basis into Catalyst common stock at a future date. "
11/1/12
• !Report Abuse
Add a reply...

140 characters

aeromitch37
Any outlooks on ENZ, CPRX, or SVNT?
10/16/12
Reply (2)

• !Report Abuse
View all 2 replies
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
10/16/12
• !Report Abuse
aeromitch37: When do we think SVNT will raise?
10/16/12
• !Report Abuse
Add a reply...

140 characters

cashedin
CPRX Do you guys think waiting to get in till next week will be too late as the stock may start to rise?
10/5/12
Reply (1)

• !Report Abuse
View all 1 replies
starstar: Never think so. According to your strategy-long term or short term, calculate your entry point and wait patiently.
10/5/12
• !Report Abuse
Add a reply...

140 characters

aeromitch37
What's the outlook on CPRX? Think as we get closer to the clinical results release it will rebound near $2?
9/28/12
Reply (7)

• !Report Abuse
View all 7 replies
Droney: 1st half on Nov.
10/3/12
• !Report Abuse
Droney: *of Nov
10/3/12
• !Report Abuse
Add a reply...

140 characters

IALF
CPRX buying opportunity after data delay.
9/26/12
Reply (4)

• !Report Abuse
View all 4 replies
IALF: Fingers crossed, Droney.
9/26/12
• !Report Abuse
Droney: i sold this morning. I may buy back before Nov 1st though. I gotta admit, im a little spooked now.
9/26/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

oldorv
$CPRX, $LLEN, LONG, 2 very fine micros...
Apr 23, 8:34 AM
Reply (3)

• !Report Abuse
View all 3 replies
Spitgray: Bought!!!
Apr 24, 3:51 PM
• !Report Abuse
oldorv: GOOD LUCK TO US
Apr 24, 3:59 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
@CPRX lesson learned = question it next time company does financing deal before data is out, also, take profits on runs!
11/8/12
Reply (14)

• !Report Abuse
View all 14 replies
Iron K: I'm in the same boat I was looking at the filing and the 5M I'm going to hold for at least 30 days to see the affect of it.
11/9/12
• !Report Abuse
Iron K: Also maybe CPP-115 increased dosage will have a positive affect? (lol)
11/9/12
• !Report Abuse
Add a reply...

140 characters

stockperks
Hope you guys all bailed out of CPRX before today's death spiral...
11/8/12
Reply (1)

• !Report Abuse
View all 1 replies
Iron K: Is it worth investing in for their other two orphan drugs coming up?
11/8/12
• !Report Abuse
Add a reply...

140 characters

JoeChang23
what's going on with CPRX guys? Stock is going down instead of rising in anticipation of Phase2b.
11/1/12
Reply (1)

• !Report Abuse
View all 1 replies
uavmx: "BioMarin has invested $5 million in Catalyst, which will convert on a mandatory basis into Catalyst common stock at a future date. "
11/1/12
• !Report Abuse
Add a reply...

140 characters

aeromitch37
Any outlooks on ENZ, CPRX, or SVNT?
10/16/12
Reply (2)

• !Report Abuse
View all 2 replies
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
10/16/12
• !Report Abuse
aeromitch37: When do we think SVNT will raise?
10/16/12
• !Report Abuse
Add a reply...

140 characters

cashedin
CPRX Do you guys think waiting to get in till next week will be too late as the stock may start to rise?
10/5/12
Reply (1)

• !Report Abuse
View all 1 replies
starstar: Never think so. According to your strategy-long term or short term, calculate your entry point and wait patiently.
10/5/12
• !Report Abuse
Add a reply...

140 characters

aeromitch37
What's the outlook on CPRX? Think as we get closer to the clinical results release it will rebound near $2?
9/28/12
Reply (7)

• !Report Abuse
View all 7 replies
Droney: 1st half on Nov.
10/3/12
• !Report Abuse
Droney: *of Nov
10/3/12
• !Report Abuse
Add a reply...

140 characters

IALF
CPRX buying opportunity after data delay.
9/26/12
Reply (4)

• !Report Abuse
View all 4 replies
IALF: Fingers crossed, Droney.
9/26/12
• !Report Abuse
Droney: i sold this morning. I may buy back before Nov 1st though. I gotta admit, im a little spooked now.
9/26/12
• !Report Abuse
Add a reply...

140 characters

GaryLee276
Now it looks like people are not going to stick around for the announcement??? What is happening to CPRX short term????
9/19/12
Reply (4)

• !Report Abuse
View all 4 replies
Droney: Dude the stock jumped 30% in a day. You don't think people are going to take profits? It will be back above $2 tomorrow.
9/19/12
• !Report Abuse
Droney: Phase 2 trial results expected next week. This is run up is in anticipation of that catalyst pumping and dumping has nothing to do with it.
9/19/12
• !Report Abuse
Add a reply...

140 characters

R.S. Analytics
CPRX - KABOOM!!!!!!!!!! I think she is going to continue running!!!!
9/18/12
Reply (4)

• !Report Abuse
View all 4 replies
Droney: Im holding as well. I agree $4 is probably a little too optimistic, $3.50 is probably more like it...for now... GL!
9/18/12
• !Report Abuse
R.S. Analytics: GL to you too!
9/19/12
• !Report Abuse
Add a reply...

140 characters

lgmets
Why is CPRX tanking so badly?
9/6/12
Reply (7)

• !Report Abuse
View all 7 replies
lgmets: 21 mark, how do I see these filings quickly? It looks like you have to purchase at $1.06 and exercise at $2.08, and buy 4M of them.
9/7/12
• !Report Abuse
21mark: That was the new is issue, that closed on 8/28. I'm talking about the May issue. http://bit.ly/L1g3DR Hope this helps
9/7/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$CPRX did an offering -- what I was afraid of, next time, I do not listen to anyone anymore touting me something.
8/28/12
Reply (29)

• !Report Abuse
View all 29 replies
johnwcoop: "As any smart trader would"? Scott didn't you put a $2.50 price target on CPRX? I don't own CPRX, but like others, I follow.
8/29/12
• !Report Abuse
Scott Matusow: Doesn't matter when I've been doing this for years, i see a pre market big gap, i sell into it, as any " good trader would" on an upgrade.
8/29/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
@SheffStation and @biorunup seem to like $CPRX. I have joined them and I am picking it as well for a catalyst trade to run over $2.50 min
8/23/12
Reply (2)

• !Report Abuse
View all 2 replies
johnjail: I readed about some insider purchases at the end of june, (from Insidermonkey.com) so I picked it at 0.64, I sold at 1.3 with a nice gain.
8/24/12
• !Report Abuse
johnjail: now I'm looking for a re entry... I hope to buy under 1.2 but I think it's not possibile ..
8/24/12
• !Report Abuse
Add a reply...

140 characters

uavmx
what happened in the news for CPRX ?! 33%?
5/24/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: public offering of 6M more shares...stock dilution
5/24/12
• !Report Abuse
Add a reply...

140 characters

CPRX Catalyst Pharmaceutical Partners, Inc.

CPRX

Catalyst Pharmaceutical Partners, Inc.